Updated: January 20, 2026
How to Help Your Patients Find Rezdiffra (Resmetirom) in Stock: A Provider's Guide
Author
Peter Daggett

Summarize with AI
- Understanding Why Patients Struggle with Access
- Step 1: Use Madrigal Patient Support as Your Central Hub
- Step 2: Prepare a Strong Prior Authorization Packet
- Step 3: Address Cost at the Point of Care
- Step 4: Educate Patients on the Specialty Pharmacy Process
- Step 5: Consider medfinder to Reduce Staff Burden
A practical guide for hepatologists and gastroenterologists on how to streamline Rezdiffra access for patients — from PA workflows to specialty pharmacy enrollment and savings programs.
Prescribing Rezdiffra (resmetirom) is only the first step. For many patients, the journey from prescription to first dose is complicated by specialty pharmacy logistics, insurance prior authorization, and unfamiliarity with the specialty drug dispensing system. As a provider, the steps you take at and around the point of prescribing can dramatically shorten your patient's wait time and reduce the risk of treatment abandonment.
This guide gives you a practical, step-by-step framework for helping your MASH patients access Rezdiffra as efficiently as possible.
Understanding Why Patients Struggle with Access
Rezdiffra is a Limited Distribution Drug (LDD), dispensed only through a specialty pharmacy network — not at CVS, Walgreens, or local independent pharmacies. Most patients have never used a specialty pharmacy before and have no idea what to expect. Common confusion points include:
Showing up at a retail pharmacy expecting to pick up their medication and being turned away
Not understanding why prior authorization is needed or how long it takes
Seeing a $47,400/year list price and assuming they cannot afford the medication
Not enrolling in the copay card or patient assistance program because they didn't know it existed
A short, proactive conversation at the point of prescribing can prevent most of these issues.
Step 1: Use Madrigal Patient Support as Your Central Hub
Madrigal Patient Support (877-219-7770) is the manufacturer's hub for getting patients started on Rezdiffra. It coordinates prior authorization, specialty pharmacy routing, and savings program enrollment. Train your office staff to initiate the Madrigal Patient Support enrollment process at the same appointment where Rezdiffra is prescribed — not days later.
What Madrigal Patient Support does for your patients:
Initiates the insurance benefit investigation
Routes the prescription to the appropriate in-network specialty pharmacy
Enrolls eligible patients in the Rezdiffra Copay Savings Card
Screens for patient assistance program eligibility
Assigns a Nurse Navigator for ongoing patient education and adherence support
Step 2: Prepare a Strong Prior Authorization Packet
Prior authorization is required by nearly all commercial plans and Medicare Part D for Rezdiffra. A well-prepared PA packet reduces delays and denials. Include the following:
Liver biopsy pathology report confirming MASH with F2 or F3 fibrosis and NAS ≥ 4
Recent LFTs (ALT, AST) and relevant liver biomarkers
Documentation of lifestyle counseling on diet and exercise (the drug's indication requires this)
Prescriber NPI, specialty designation, and contact information
A pre-written letter of medical necessity for high-risk-of-denial patients
If a PA is denied, request a peer-to-peer review. In many cases, a direct conversation between you and the plan's medical director results in approval. Emphasize the F2-F3 fibrosis staging, lack of pharmacologic alternatives prior to Rezdiffra's approval, and the serious consequences of disease progression without treatment.
Step 3: Address Cost at the Point of Care
Many patients see the ~$47,400/year list price online and panic. Proactively address cost before they do. Here is what to communicate:
Commercial insurance: The Madrigal Copay Savings Card can bring the patient's out-of-pocket cost to as little as $0/month. Eligibility: must have commercial (non-government) insurance.
Medicare Part D: The $2,000 annual out-of-pocket cap (effective 2025) provides meaningful relief. Costs vary by plan and phase of coverage.
Uninsured or financially ineligible patients: Madrigal Patient Assistance Program may provide Rezdiffra at no cost. Madrigal Patient Support can screen for eligibility.
Step 4: Educate Patients on the Specialty Pharmacy Process
Set expectations before patients leave your office. Tell them:
"You cannot pick this up at a regular pharmacy — it will be mailed directly to your home."
"It may take 1–3 weeks for insurance to approve, and possibly longer if an appeal is needed."
"You will receive a call from the specialty pharmacy to confirm your address and insurance details."
"If you don't hear from anyone within a week, call Madrigal Patient Support at 877-219-7770 to follow up."
Step 5: Consider medfinder to Reduce Staff Burden
When patients are confused about which specialty pharmacy carries Rezdiffra, or are calling your office repeatedly for help navigating the process, medfinder for providers offers a practical solution — calling pharmacies near the patient to find which ones can fill the prescription. This reduces inbound patient calls to your office and helps patients get the answers they need faster. For a comprehensive clinical overview, see: Rezdiffra: What Providers Need to Know in 2026.
Frequently Asked Questions
Prior authorization for Rezdiffra can take anywhere from 3 business days to 3 weeks, depending on the payer and completeness of the submitted documentation. Having the liver biopsy report, LFTs, and lifestyle counseling documentation ready at the time of prescribing significantly reduces delays. Medicare Advantage and Medicaid plans may take longer than commercial plans.
First, request a peer-to-peer review with the plan's medical director. Prepare a letter of medical necessity emphasizing the patient's F2-F3 fibrosis staging, MASH severity, and the clinical consequences of untreated disease. First-time denials are frequently overturned on appeal. Also explore whether the patient qualifies for Madrigal's Patient Assistance Program if insurance continues to be a barrier.
Yes. Data from the MAESTRO-NASH trial shows resmetirom maintains its MASH efficacy regardless of background GLP-1 RA or SGLT2i use. In fact, modest weight loss from GLP-1 therapy may enhance resmetirom's histologic response. For patients already on semaglutide or other GLP-1 agents for T2D or obesity, resmetirom can be co-prescribed when MASH fibrosis warrants it.
Rezdiffra is available through Madrigal's specialty pharmacy network, which includes major specialty pharmacies such as Accredo, CVS Specialty, Optum Specialty Pharmacy, and AllianceRx Walgreens Pharmacy. The specific pharmacy used depends on your patient's insurance plan network. Madrigal Patient Support (877-219-7770) will route the prescription to the appropriate pharmacy after insurance verification.
Monitor ALT and AST at baseline, 4–8 weeks after starting, and then periodically during treatment. Discontinue Rezdiffra if hepatotoxicity is suspected (jaundice, right upper quadrant pain, markedly elevated LFTs). If LFTs do not return to baseline after discontinuation, consider drug-induced autoimmune-like hepatitis (DI-ALH) in the differential.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Resmetirom also looked for:
More about Resmetirom
35,897 have already found their meds with Medfinder.
Start your search today.





